Roche Xeloda Contraindicated For Patients With Severe Renal Impairment
Roche's breast cancer treatment Xeloda will carry a contraindication for use in patients with severe renal impairment following a clinical pharmacology study and a subsequent analysis of the clinical safety database.
You may also be interested in...
Roche will study Xeloda in combination with Pharmacia's Camptosar in colorectal cancer patients following FDA approval of Xeloda April 30 for use in metastatic colorectal cancer patients.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011